BSc; MSc; PhD
Since 09/2013 I have been a postdoctoral researcher Prof Paresh Vyas' research group at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. Human hematopoietic progenitors downstream of the hematopoietic stem cells remain poorly defined and incompletely purified. My research is focused on understanding how these progenitors differentiate along the different blood lineages and unveiling the functional and transcriptional heterogeneity within these populations. Furthermore, hematopoietic progenitors are the normal cellular counterparts of Acute Myeloid Leukemia-propagating cells. Therefore, my research interest is also to understand the molecular mechanisms deregulated in normal progenitors, which result in differentiation block in leukemia. To answer these questions I use primarily single cell assays, including flow cytometry analyses and sorting, mass cytometry, single cell and limit dilution in vitro cultures, single cell multiplex qPCR, single cell RNA-sequencing.
Before I joined Vyas Research Group, from 05/2008 till 06/2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany. PhD thesis title: 'Structural plasticity and post-translational modifications of C/EBPb direct distinct myeloid cell fates'.
A recurrent activating missense mutation in Waldenström macroglobulinemia affects the DNA binding of the ETS transcription factor SPI1 and enhances proliferation.
Roos-Weil D. et al, (2019), Cancer Discov
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L. et al, (2018), Nat Med
Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.
Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97
Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis
Vyas P. et al, (2017), BLOOD, 130
Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
Quek L. et al, (2017), BLOOD, 130